Font size
Color
Home
Services
Mission Area
Industry and Investment Strategy
Pharmaceuticals & Regenerative Medicine
Advanced Medical Devices Technology & Medical Robotics
Nutraceuticals and Cosmeceuticals
Innovation Utilization for Socioeconomics
APEC Life Sciences
The Southeast ASIA-Europe Joint Funding Scheme on Research and Innovation (JFS)
Data Resources
Technology Trends Analysis
Investment Regulation and Incentives
Market Statistic Analysis
Business and Investment News
หนังสืออิเล็กทรอนิกส์
Thailand Life Sciences
Thai Clinical Trials Registry (TCTR)
CSDT e-Learning
CSDT e-Learning
Database of Essential Principle (Eps) and National Quality Infrastructure (NQI) for Medical Devices
E-Document System for CSDT
Genomics
News
Coming Soon
Press Release
Event Calendar
Purchase
Procurement
Join us
Jobs
Results Announcement
VDO
About TCELS
Overview
Organizational Structure
Executive Committee and TCELS Executives
Our Partners
Our Partners
Contact Us
search
© ศลช. 2018, All right reserved
EN
TH
Data Resources
>
Investment Regulation and Incentives
>
The distribution channel of Antituberculous drugs
The distribution channel of Antituberculous drugs
19/06/2020
According to the World Health Organization (WHO), Thailand is struggling with tuberculosis (TB) and is one of the 14 countries worst hit by this severely infectious disease. The statistical data shows that Thailand has around 120,000 TB cases with 12,000 people dying of the disease. Interestingly, 30 percent of TB cases have not received proper treatment, even though TB can be cured successfully within six months. TB does not always cause the classic symptoms of coughing, weight loss, night sweats, and blood-streaked sputum, but these symptoms may develop, and death may occur if the disease is not properly treated. Untreated disease also puts others at risk of infection and only a full course of treatment will address the problem.
Please fill the following information to continue reading.
Email
Page view :
155